To provide new insights on the different disease stages (SS or NASH), we studied two independent MoA, considering whether the motive occurs in early or later stages of the disease: (1) RUNX1 promoting IR and (2) RUNX1 promoting lipotoxicity and hepatic injury and fibrosis, respectively. Here, RUNX1 is linked to metabolic dysfunction-associated steatohepatitis.